Diabetic ketoacidosis shortly after COVID‐19 vaccination in a non–small‐cell lung cancer patient receiving combination of PD‐1 and CTLA‐4 inhibitors: A case report

We describe a case of diabetic ketoacidosis (DKA) shortly after the SARS‐CoV‐2 (COVID‐19) vaccination in a 65‐year‐old woman with non–small‐cell lung cancer under a combination treatment of programmed cell death protein 1 (PD‐1) and cytotoxic T‐lymphocyte‐associated protein 4 (CTLA‐4) inhibitors. Sh...

Descripción completa

Detalles Bibliográficos
Autores principales: Makiguchi, Tomonori, Fukushima, Takashi, Tanaka, Hisashi, Taima, Kageaki, Takayasu, Shinobu, Tasaka, Sadatomo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013655/
https://www.ncbi.nlm.nih.gov/pubmed/35166047
http://dx.doi.org/10.1111/1759-7714.14352
_version_ 1784688042056876032
author Makiguchi, Tomonori
Fukushima, Takashi
Tanaka, Hisashi
Taima, Kageaki
Takayasu, Shinobu
Tasaka, Sadatomo
author_facet Makiguchi, Tomonori
Fukushima, Takashi
Tanaka, Hisashi
Taima, Kageaki
Takayasu, Shinobu
Tasaka, Sadatomo
author_sort Makiguchi, Tomonori
collection PubMed
description We describe a case of diabetic ketoacidosis (DKA) shortly after the SARS‐CoV‐2 (COVID‐19) vaccination in a 65‐year‐old woman with non–small‐cell lung cancer under a combination treatment of programmed cell death protein 1 (PD‐1) and cytotoxic T‐lymphocyte‐associated protein 4 (CTLA‐4) inhibitors. She had no history of diabetic mellitus. A few days after the second shot of COVID‐19 vaccination, she developed DKA. We speculate that the immune‐related adverse event and immunogenicity of vaccination synergistically induced DKA.
format Online
Article
Text
id pubmed-9013655
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-90136552022-04-20 Diabetic ketoacidosis shortly after COVID‐19 vaccination in a non–small‐cell lung cancer patient receiving combination of PD‐1 and CTLA‐4 inhibitors: A case report Makiguchi, Tomonori Fukushima, Takashi Tanaka, Hisashi Taima, Kageaki Takayasu, Shinobu Tasaka, Sadatomo Thorac Cancer Case Reports We describe a case of diabetic ketoacidosis (DKA) shortly after the SARS‐CoV‐2 (COVID‐19) vaccination in a 65‐year‐old woman with non–small‐cell lung cancer under a combination treatment of programmed cell death protein 1 (PD‐1) and cytotoxic T‐lymphocyte‐associated protein 4 (CTLA‐4) inhibitors. She had no history of diabetic mellitus. A few days after the second shot of COVID‐19 vaccination, she developed DKA. We speculate that the immune‐related adverse event and immunogenicity of vaccination synergistically induced DKA. John Wiley & Sons Australia, Ltd 2022-02-14 2022-04 /pmc/articles/PMC9013655/ /pubmed/35166047 http://dx.doi.org/10.1111/1759-7714.14352 Text en © 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Reports
Makiguchi, Tomonori
Fukushima, Takashi
Tanaka, Hisashi
Taima, Kageaki
Takayasu, Shinobu
Tasaka, Sadatomo
Diabetic ketoacidosis shortly after COVID‐19 vaccination in a non–small‐cell lung cancer patient receiving combination of PD‐1 and CTLA‐4 inhibitors: A case report
title Diabetic ketoacidosis shortly after COVID‐19 vaccination in a non–small‐cell lung cancer patient receiving combination of PD‐1 and CTLA‐4 inhibitors: A case report
title_full Diabetic ketoacidosis shortly after COVID‐19 vaccination in a non–small‐cell lung cancer patient receiving combination of PD‐1 and CTLA‐4 inhibitors: A case report
title_fullStr Diabetic ketoacidosis shortly after COVID‐19 vaccination in a non–small‐cell lung cancer patient receiving combination of PD‐1 and CTLA‐4 inhibitors: A case report
title_full_unstemmed Diabetic ketoacidosis shortly after COVID‐19 vaccination in a non–small‐cell lung cancer patient receiving combination of PD‐1 and CTLA‐4 inhibitors: A case report
title_short Diabetic ketoacidosis shortly after COVID‐19 vaccination in a non–small‐cell lung cancer patient receiving combination of PD‐1 and CTLA‐4 inhibitors: A case report
title_sort diabetic ketoacidosis shortly after covid‐19 vaccination in a non–small‐cell lung cancer patient receiving combination of pd‐1 and ctla‐4 inhibitors: a case report
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013655/
https://www.ncbi.nlm.nih.gov/pubmed/35166047
http://dx.doi.org/10.1111/1759-7714.14352
work_keys_str_mv AT makiguchitomonori diabeticketoacidosisshortlyaftercovid19vaccinationinanonsmallcelllungcancerpatientreceivingcombinationofpd1andctla4inhibitorsacasereport
AT fukushimatakashi diabeticketoacidosisshortlyaftercovid19vaccinationinanonsmallcelllungcancerpatientreceivingcombinationofpd1andctla4inhibitorsacasereport
AT tanakahisashi diabeticketoacidosisshortlyaftercovid19vaccinationinanonsmallcelllungcancerpatientreceivingcombinationofpd1andctla4inhibitorsacasereport
AT taimakageaki diabeticketoacidosisshortlyaftercovid19vaccinationinanonsmallcelllungcancerpatientreceivingcombinationofpd1andctla4inhibitorsacasereport
AT takayasushinobu diabeticketoacidosisshortlyaftercovid19vaccinationinanonsmallcelllungcancerpatientreceivingcombinationofpd1andctla4inhibitorsacasereport
AT tasakasadatomo diabeticketoacidosisshortlyaftercovid19vaccinationinanonsmallcelllungcancerpatientreceivingcombinationofpd1andctla4inhibitorsacasereport

Ejemplares similares